Gamida Cell-Teva

Gamida Cell is a commercial-stage biopharmaceutical company pioneering the development of cell therapies designed to cure cancer and rare, serious blood diseases. The company's proprietary NAM technology platform enhances the therapeutic potential of cells by expanding them in culture while maintaining their functional phenotype. Their lead product, Omisirge (omidubicel-onlv), is the first US FDA-approved nicotinamide-modified allogeneic hematopoietic stem cell therapy for patients with hematologic malignancies. Beyond stem cells, Gamida Cell is applying its NAM technology to develop an innate immune system pipeline, including NAM-enabled natural killer (NK) cell therapies for solid tumors and hematologic cancers.